Hypermarcas (OTCMKTS:HYPMY) Shares Gap Up - What's Next?

Key Points

• Hypermarcas' stock price increased from $3.82 to $3.93 upon opening, indicating a rise of about 2.9% before trading at $3.94 with a volume of 945 shares.
• Scotiabank upgraded Hypermarcas to a "strong-buy" rating, contributing to a consensus rating of "Strong Buy" from analysts.
• The company reported a net margin of 11.28% and earnings per share of $0.12 for the last quarter, reflecting its financial performance amidst a market capitalization of $2.56 billion.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $3.82, but opened at $3.93. Hypermarcas shares last traded at $3.94, with a volume of 945 shares traded.

Wall Street Analysts Forecast Growth

Separately, Scotiabank raised Hypermarcas to a "strong-buy" rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Strong Buy".

Hypermarcas Stock Up 5.8%

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80. The company has a market cap of $2.56 billion, a PE ratio of 19.22 and a beta of 0.83. The company has a fifty day moving average price of $4.22 and a 200 day moving average price of $4.28.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.